These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32634395)

  • 1. Intravitreal enzyme replacement inhibits progression of retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis.
    Whiting REH; Robinson Kick G; Ota-Kuroki J; Lim S; Castaner LJ; Jensen CA; Kowal J; Nguyen A; Corado C; O'Neill CA; Katz ML
    Exp Eye Res; 2020 Sep; 198():108135. PubMed ID: 32634395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal enzyme replacement preserves retinal structure and function in canine CLN2 neuronal ceroid lipofuscinosis.
    Whiting REH; Pearce JW; Vansteenkiste DP; Bibi K; Lim S; Robinson Kick G; Castaner LJ; Sinclair J; Chandra S; Nguyen A; O'Neill CA; Katz ML
    Exp Eye Res; 2020 Aug; 197():108130. PubMed ID: 32622066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal implantation of TPP1-transduced stem cells delays retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis.
    Tracy CJ; Whiting RE; Pearce JW; Williamson BG; Vansteenkiste DP; Gillespie LE; Castaner LJ; Bryan JN; Coates JR; Jensen CA; Katz ML
    Exp Eye Res; 2016 Nov; 152():77-87. PubMed ID: 27637672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis.
    Vuillemenot BR; Kennedy D; Cooper JD; Wong AM; Sri S; Doeleman T; Katz ML; Coates JR; Johnson GC; Reed RP; Adams EL; Butt MT; Musson DG; Henshaw J; Keve S; Cahayag R; Tsuruda LS; O'Neill CA
    Mol Genet Metab; 2015 Feb; 114(2):281-93. PubMed ID: 25257657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal gene therapy preserves retinal function in a canine model of CLN2 neuronal ceroid lipofuscinosis.
    Kick GR; Whiting REH; Ota-Kuroki J; Castaner LJ; Morgan-Jack B; Sabol JC; Meiman EJ; Ortiz F; Katz ML
    Exp Eye Res; 2023 Jan; 226():109344. PubMed ID: 36509165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme replacement therapy delays pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis.
    Whiting RE; Narfström K; Yao G; Pearce JW; Coates JR; Castaner LJ; Jensen CA; Dougherty BN; Vuillemenot BR; Kennedy D; O'Neill CA; Katz ML
    Exp Eye Res; 2014 Aug; 125():164-72. PubMed ID: 24954537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracerebroventricular gene therapy that delays neurological disease progression is associated with selective preservation of retinal ganglion cells in a canine model of CLN2 disease.
    Whiting REH; Jensen CA; Pearce JW; Gillespie LE; Bristow DE; Katz ML
    Exp Eye Res; 2016 May; 146():276-282. PubMed ID: 27039708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multifocal retinopathy in Dachshunds with CLN2 neuronal ceroid lipofuscinosis.
    Whiting RE; Pearce JW; Castaner LJ; Jensen CA; Katz RJ; Gilliam DH; Katz ML
    Exp Eye Res; 2015 May; 134():123-32. PubMed ID: 25697710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease).
    Katz ML; Coates JR; Sibigtroth CM; Taylor JD; Carpentier M; Young WM; Wininger FA; Kennedy D; Vuillemenot BR; O'Neill CA
    J Neurosci Res; 2014 Nov; 92(11):1591-8. PubMed ID: 24938720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal enzyme replacement for inherited retinal diseases.
    Rodriguez-Martinez AC; Wawrzynski J; Henderson RH
    Curr Opin Ophthalmol; 2024 May; 35(3):232-237. PubMed ID: 38170785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human tripeptidyl peptidase-1 infusion to the monkey CNS: safety, pharmacokinetics, and distribution.
    Vuillemenot BR; Kennedy D; Reed RP; Boyd RB; Butt MT; Musson DG; Keve S; Cahayag R; Tsuruda LS; O'Neill CA
    Toxicol Appl Pharmacol; 2014 May; 277(1):49-57. PubMed ID: 24642058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First in man study of intravitreal tripeptidyl peptidase 1 for CLN2 retinopathy.
    Wawrzynski J; Martinez AR; Thompson DA; Ram D; Bowman R; Whiteley R; Gan C; Harding L; Mortensen A; Mills P; Gissen P; Henderson RH
    Eye (Lond); 2024 Apr; 38(6):1176-1182. PubMed ID: 38049626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis.
    Vuillemenot BR; Katz ML; Coates JR; Kennedy D; Tiger P; Kanazono S; Lobel P; Sohar I; Xu S; Cahayag R; Keve S; Koren E; Bunting S; Tsuruda LS; O'Neill CA
    Mol Genet Metab; 2011 Nov; 104(3):325-37. PubMed ID: 21784683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinal pathology in a canine model of late infantile neuronal ceroid lipofuscinosis.
    Katz ML; Coates JR; Cooper JJ; O'Brien DP; Jeong M; Narfström K
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2686-95. PubMed ID: 18344450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraventricular Cerliponase Alfa Treatment in a Patient with Advanced Neuronal Ceroid Lipofuscinosis Type 2.
    Nakashima S; Hamada M; Kimura T; Tanifuji S; Takahashi A; Yashita D; Kakimoto Y; Matsukawa T; Ishiura H; Toda T
    Intern Med; 2024 Jun; 63(12):1807-1812. PubMed ID: 37926545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.
    Fietz M; AlSayed M; Burke D; Cohen-Pfeffer J; Cooper JD; Dvořáková L; Giugliani R; Izzo E; Jahnová H; Lukacs Z; Mole SE; Noher de Halac I; Pearce DA; Poupetova H; Schulz A; Specchio N; Xin W; Miller N
    Mol Genet Metab; 2016 Sep; 119(1-2):160-7. PubMed ID: 27553878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large-volume intrathecal enzyme delivery increases survival of a mouse model of late infantile neuronal ceroid lipofuscinosis.
    Xu S; Wang L; El-Banna M; Sohar I; Sleat DE; Lobel P
    Mol Ther; 2011 Oct; 19(10):1842-8. PubMed ID: 21730969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A reversal learning task detects cognitive deficits in a Dachshund model of late-infantile neuronal ceroid lipofuscinosis.
    Sanders DN; Kanazono S; Wininger FA; Whiting RE; Flournoy CA; Coates JR; Castaner LJ; O'Brien DP; Katz ML
    Genes Brain Behav; 2011 Oct; 10(7):798-804. PubMed ID: 21745338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurofilament light is a treatment-responsive biomarker in CLN2 disease.
    Ru Y; Corado C; Soon RK; Melton AC; Harris A; Yu GK; Pryer N; Sinclair JR; Katz ML; Ajayi T; Jacoby D; Russell CB; Chandriani S
    Ann Clin Transl Neurol; 2019 Dec; 6(12):2437-2447. PubMed ID: 31814335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis).
    Kohlschütter A; Schulz A
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():682-8. PubMed ID: 27491216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.